Expert Interview
Discussing Antibody Drug Conjugates for ovarian cancer with a focus on Immunogen's ELAHERE in advance of the upcoming MIRASOL confirmatory trial data & Mersana's Upifitamab Rilsodotin (UpRi)
Ticker(s): IMGN, MRSN, STROInstitution: Massachusetts General Hospital
- Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School & Chief Medical Officer of the Massachusetts General Physicians Organization.
- Currently manages 450 patients with ovarian cancer and has experience prescribing ADC's
- PI of clinical trials evaluating novel therapies in the treatment of ovarian cancer, as well as the design of a novel device for delivery of intra-peritoneal catheter.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
